UFP Technologies, Inc. (UFPT) is a publicly traded company in the Healthcare — Medical - Devices industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
UFP Technologies, Inc. specializes in the engineering and custom fabrication of components, subassemblies, finished products, and packaging, primarily utilizing advanced foams, films, and plastics. A significant portion of its business is dedicated to the medical sector, where its single-use and single-patient devices and parts are integral to a broad spectrum of applications, including general medical devices, disposable wound care, infection control, minimally invasive surg...
Analysis Summary
UFP Technologies, Inc. reported revenue of $602.8M in the most recent fiscal year, growing at a 5-year CAGR of 27.4%. Net income reached $68.3M, with a 38.6% 5-year CAGR.
Trailing-twelve-month margins: gross margin 28.5%, operating margin 15.2%, net margin 11.4%. Free cash flow grew at 30.7% CAGR over 5 years.
At the current price of $275.41, UFPT trades at a P/E of 29.85 and an ROE of 16.72%. Market capitalisation stands at $2.1B.
Balance sheet quality for UFPT: current ratio of 2.7, net debt of $134.2M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is strong: free cash flow of $79.0M represents 116% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $275.41 |
| Market Cap | $2.1B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 29.85 |
| Price / Book | 4.67 |
| EV / EBITDA | 19.84 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 16.72% |
| Return on Invested Capital | 12.65% |
| Return on Assets | 10.60% |
| Gross Margin | 28.50% |
| Operating Margin | 15.25% |
| Net Margin | 11.45% |
Financial Health
| Debt / Equity | 0.29 |
| Current Ratio | 3.00 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| UFPT | UFP Technologies, Inc. | $2.2B | 29.85 | 4.67 | 16.7% |
| IMNM | Immunome, Inc. | $2.3B | 5.06 | -50.6% | |
| ESTA | Establishment Labs Holdings Inc. | $2.1B | 99.20 | -203.9% | |
| PGNY | Progyny, Inc. | $2.2B | 28.62 | 4.79 | 11.3% |
| ABT | Abbott Laboratories | $177.1B | 32.49 | 3.45 | 10.5% |
| 0Y6X.L | Medtronic Plc | $125.7B | |||
| MDT | Medtronic plc | $118.5B | 22.97 | 2.39 | 10.6% |
| SYK | Stryker Corporation | $109.2B | 29.95 | 4.66 | 16.4% |
Price Performance
| 1 month | -11.01% |
| 3 months | +16.77% |
| Year-to-date | +25.84% |
| 1 year | +36.32% |
| 3 years | +74.51% |
52-Week Range
| 52-week High | $338.71 |
| 52-week Low | $173.86 |
| Avg Volume (90d) | 185K |
Related companies: AHCO · ALVO · CNMD · ESTA · IMNM · OMCL · PGNY
Explore sector: Healthcare · Medical - Devices
More sections of UFPT: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks